A Phase 1, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients With Refractory or Relapsed Solid Tumor Malignancies
Although progress has been made, patients with malignancies often either progress after the
traditional approach of chemotherapy, surgery, or radiotherapy, or are not candidates for
these approaches because of the advances stage of disease. Novel therapies that may offer
greater potential than those currently available are urgently needed.
AV 412 is a potent inhibitor of human epidermal growth factor family receptor tyrosine
kinases (TKIs) and represents a growing class of anti-cancer agents. The recent introduction
of TKIs has opened the door to new approaches to cancer treatment in which the goals of
therapy are to halt disease progression, ameliorate symptoms, and improve patient quality of
life. AV412 may inhibit growth of solid tumors, with fewer and less debilitating side
effects.
This study is designed to determine the safety, tolerability and maximum tolerated dose of
daily oral administration of AV 412. Patients will be assigned to escalating drug dose
cohorts to determine the optimal dose. Evaluations to determine tolerability include PK, PD,
and the adverse events which occur during the course of study drug administration.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the safety, tolerability, and dose-limiting toxicities (DLT), and determine the maximum tolerated dose (MTD) of AV-412 when administered once daily by the oral route for 4 weeks (4 weeks equals one dosing cycle)
one year
Yes
Manuel Hidalgo, MD, PhD
Principal Investigator
Johns Hopkins University
United States: Food and Drug Administration
AV-412-06-101
NCT00381654
October 2006
February 2010
Name | Location |
---|---|
Johns Hopkins University School of Medicine | Baltimore, Maryland 21205 |